| Filed On | Filing |
|---|---|
| 31 Mar 2025 |
8-K/A: Financial Statements and Exhibits
On March 25, 2025 (the “Closing Date”), Whitehawk Therapeutics, Inc. (the “Company”) completed the previously announced sale of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. (the “Divestiture”) pursuant to the ... |
| 08 Nov 2023 |
8-K/A: Results of Operations and Financial Condition
PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations on track for presentation of early interim analysis by mid-December 2023; multiple 2024 catalysts expected |
| 28 Mar 2023 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 24 Sep 2021 |
8-K/A: Financial Statements and Exhibits
Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2020 and 2019 |
Loading...
